BeOne Medicines Ltd.

BeOne Medicines Ltd., formerly known as BeiGene, Ltd., is a multinational biopharmaceutical company specializing in oncology. Founded in 2010 by John V. Oyler and Xiaodong Wang, it focuses on discovering, developing, and commercializing innovative cancer treatments, including targeted therapies and immunotherapies for hematological malignancies and solid tumors.

Headquartered in Cambridge, Massachusetts, with additional key locations in Basel, Switzerland, Beijing, China, and operations across six continents in over 45 countries, the company employs approximately 12,000 people. It trades publicly on Nasdaq (ONC), SEHK (6160), and SSE (688235).

Key commercial products include BRUKINSA (zanubrutinib), a BTK inhibitor for blood cancers; TEVIMBRA (tislelizumab), an anti-PD-1 antibody for solid tumors and blood cancers; and SYLVANT for multicentric Castleman disease. BeOne advances a broad pipeline of over 40 clinical and commercial-stage assets through internal capabilities, partnerships, and a global manufacturing network, including sites supporting oral solid dosage production.

In the chemical industry context, it develops small-molecule drugs and maintains pharmaceutical manufacturing facilities to produce active pharmaceutical ingredients and formulations for global distribution.